Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR 深 沪
已收盘 05-15 16:00:00 美东时间
28.05
-0.710
-2.47%
华盛通- 最 高28.75
- 今 开28.73
- 成交量 19.49万股
- 最 低 27.825
- 昨 收 28.76
- 总市值 14.26亿
- 52周最高 40.7147
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 27.555
- 委 比 93.03%
- 总股本 5083.19万
- 历史最高 76.98
- 量 比 1.35
- 振 幅 3.22%
- 历史最低 18.43
- 每 手 1
- 风险率 2.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Immunocore Hldgs Q1 EPS $0.25 Beats $(0.25) Estimate, Sales $106.677M Miss $107.731M Estimate
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.25) by 200 percent. This is a 150 percent increase over earnings of $0.10 per share from the
05-06 19:07
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
04-15 00:25
UPDATE 3-IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application
UPDATE 3-IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application Adds conference call comments throughout, updates shares in paragraph 1, analyst comment in paragraph 6 By Puyaan Singh April 13 (Reuters) - IDEAYA Biosciences IDYA.O and French pharma company Servier said
04-13 18:16
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore Holdings plc (Nasdaq: IMCR), a biotech company developing innovative TCR bispecific immunotherapies for treating cancer, autoimmune, and infectious diseases, announced its management will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The event will feature a fireside chat at 3:00 p.m. EDT, accessible via Immunocore’s investor website, with a replay available afterward. Immunocore’s ImmTAX platf...
04-06 11:00
FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
03-31 22:51
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore will present five-year overall survival data from the Phase 3 trial of KIMMTRAK for metastatic uveal melanoma at the 2026 AACR meeting. The presentation will include additional data on subsequent treatments and prognostic factors. KIMMTRAK is the firstImmTAC molecule approved for treating HLA-A*02:01-positive patients with this rare and aggressive cancer. The product carries important safety warnings for cytokine release syndrome, skin...
03-17 20:30
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Jefferies Downgrades Immunocore Holdings to Hold, Lowers Price Target to $33
Jefferies analyst Clara Dong downgrades Immunocore Holdings (NASDAQ:IMCR) from Buy to Hold and lowers the price target from $48 to $33.
03-16 20:53
